Eli Lilly has reported positive results from its phase 3b Together-PsO trial evaluating the combined use of Taltz (ixekizumab) and Zepbound (tirzepatide) in adults with plaque psoriasis and obesity or overweight.
At 36 weeks, 27.1% of patients receiving both drugs achieved complete skin clearance and at least 10% weight loss, compared to 5.8% of patients receiving Taltz alone, meeting the study’s primary endpoint, according to a Feb. 18 news release. In a key secondary measure, 40.6% of patients in the combination group reached complete skin clearance, compared to 29.0% in the monotherapy group.
The 274-participant study enrolled a population with an average BMI of more than 39 kilograms per square meter — the highest of any phase 3 psoriasis biologic trial to date. Nearly all patients had psoriasis affecting high-impact areas and most had approximately 25% body surface area involvement.
The study marks Taltz as the first biologic with data from two trials supporting use alongside an incretin therapy. Zepbound is the only FDA-approved dual GIP and GLP-1 receptor agonist for obesity management.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
